Altimmune Scheduled to Announce Q4 Earnings on March 5
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ALT?
Source: seekingalpha
- Earnings Announcement: Altimmune is set to announce its Q4 earnings on March 5 before market open, with a consensus EPS estimate of -$0.24, indicating ongoing challenges in profitability.
- Earnings Estimate Revisions: Over the past three months, Altimmune's EPS estimates have seen two upward revisions with no downward adjustments, reflecting cautious optimism from analysts that could influence investor sentiment.
- Funding Activity: Altimmune recently priced a $75 million direct offering, which will provide crucial funding to support its R&D projects, particularly in advancing the clinical trials for Pemvidutide.
- FDA Breakthrough Designation: Altimmune has gained FDA breakthrough designation for its MASH therapy, a development that not only enhances the company's market position but may also expedite the product's path to market, increasing future revenue potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.160
Low
12.00
Averages
16.00
High
20.00
Current: 4.160
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune Scheduled to Announce Q4 Earnings on March 5
- Earnings Announcement: Altimmune is set to announce its Q4 earnings on March 5 before market open, with a consensus EPS estimate of -$0.24, indicating ongoing challenges in profitability.
- Earnings Estimate Revisions: Over the past three months, Altimmune's EPS estimates have seen two upward revisions with no downward adjustments, reflecting cautious optimism from analysts that could influence investor sentiment.
- Funding Activity: Altimmune recently priced a $75 million direct offering, which will provide crucial funding to support its R&D projects, particularly in advancing the clinical trials for Pemvidutide.
- FDA Breakthrough Designation: Altimmune has gained FDA breakthrough designation for its MASH therapy, a development that not only enhances the company's market position but may also expedite the product's path to market, increasing future revenue potential.
See More
Altimmune to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Altimmune will participate in multiple investor conferences from March 9 to March 12, 2026, including the Leerink Global Healthcare Conference and Barclays 28th Annual Global Healthcare Conference, offering one-on-one meetings and fireside chats to enhance interaction and transparency with investors.
- Product Development Progress: The company's lead candidate, pemvidutide, is a unique dual-action therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) and other serious liver diseases, showing significant market potential that could provide new revenue streams for the company.
- Market Positioning: By attending these conferences, Altimmune not only showcases its innovative capabilities in the biopharmaceutical sector but also attracts potential investors' attention, thereby enhancing its position in the competitive biopharmaceutical market.
- Enhanced Information Transparency: The company will provide webcasts of the fireside chats on its website's events section, ensuring investors can access the latest information promptly, further strengthening investor trust and engagement.
See More
Analysis of Weight Loss Drug Market Prospects
- Challenges for Altimmune: Altimmune's leading candidate pemvidutide showed reasonable efficacy in a 2023 phase 2 trial, but high patient discontinuation rates due to adverse reactions highlight the risks and uncertainties it faces in the weight loss drug market.
- FDA Breakthrough Therapy Designation: Despite mixed phase 2 data in MASH, pemvidutide received Breakthrough Therapy designation from the FDA, indicating its potential in high unmet need areas; if it successfully passes phase 3 trials, it could significantly enhance Altimmune's market value.
- Novo Nordisk's Market Position: Facing competition from Eli Lilly, Novo Nordisk has lowered its sales guidance, yet with the approval of Wegovy and the launch of a new oral GLP-1 drug, it is poised for recovery in the coming years, demonstrating a stronger market outlook.
- Investor Outlook: 2026 is seen as a transition year for Novo Nordisk; although sales may decline this year, the anticipated impact of new approvals and label expansions is expected to gradually boost revenue, showcasing its long-term investment value in the weight loss drug market.
See More
Altimmune to Report Q4 2025 Financial Results on March 5
- Earnings Report Schedule: Altimmune is set to release its Q4 2025 financial results on March 5, 2026, providing crucial insights into the company's financial health and future growth trajectory, which is vital for investor confidence.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and answer investor questions, with the call being webcast live on the company's Investor Relations website to ensure transparency and timely information dissemination.
- Replay Availability: A replay of the conference call will be accessible on the Investor Relations website shortly after the call, available for up to three months, allowing investors who cannot attend live to catch up on key insights and discussions.
- Company Background: Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, with its lead candidate pemvidutide targeting metabolic dysfunction-associated steatohepatitis and showing promising market potential, which could significantly impact its growth prospects.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
- Analyst Support: On February 13, Titan Partners initiated coverage of Altimmune (NASDAQ:ALT) with a Buy rating and a $7 target, highlighting promising Phase II results for pemvidutide, suggesting potential for stock price appreciation if Phase III data is strong.
- Successful Financing: On January 29, Altimmune closed a direct offering of 17.05 million shares, generating $75 million in gross proceeds, with plans to use net proceeds to fund the upcoming Phase 3 trial of pemvidutide, thereby enhancing financial flexibility.
- FDA Designation: Pemvidutide has received Breakthrough Therapy Designation from the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH), indicating its potential in addressing obesity and liver diseases, which boosts investor confidence.
- Long-Term Outlook: Despite Evercore ISI lowering Altimmune's price target from $25 to $22, the firm reiterated its Outperform rating, reflecting optimism about pemvidutide's long-term prospects and the rationale behind its therapeutic approach.
See More
Altimmune Scheduled to Announce Q4 Earnings on March 5
- Earnings Announcement: Altimmune is set to announce its Q4 earnings on March 5 before market open, with a consensus EPS estimate of -$0.24, indicating ongoing challenges in profitability.
- Earnings Estimate Revisions: Over the past three months, Altimmune's EPS estimates have seen two upward revisions with no downward adjustments, reflecting cautious optimism from analysts that could influence investor sentiment.
- Funding Activity: Altimmune recently priced a $75 million direct offering, which will provide crucial funding to support its R&D projects, particularly in advancing the clinical trials for Pemvidutide.
- FDA Breakthrough Designation: Altimmune has gained FDA breakthrough designation for its MASH therapy, a development that not only enhances the company's market position but may also expedite the product's path to market, increasing future revenue potential.
See More
Altimmune to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Altimmune will participate in multiple investor conferences from March 9 to March 12, 2026, including the Leerink Global Healthcare Conference and Barclays 28th Annual Global Healthcare Conference, offering one-on-one meetings and fireside chats to enhance interaction and transparency with investors.
- Product Development Progress: The company's lead candidate, pemvidutide, is a unique dual-action therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) and other serious liver diseases, showing significant market potential that could provide new revenue streams for the company.
- Market Positioning: By attending these conferences, Altimmune not only showcases its innovative capabilities in the biopharmaceutical sector but also attracts potential investors' attention, thereby enhancing its position in the competitive biopharmaceutical market.
- Enhanced Information Transparency: The company will provide webcasts of the fireside chats on its website's events section, ensuring investors can access the latest information promptly, further strengthening investor trust and engagement.
See More
Analysis of Weight Loss Drug Market Prospects
- Challenges for Altimmune: Altimmune's leading candidate pemvidutide showed reasonable efficacy in a 2023 phase 2 trial, but high patient discontinuation rates due to adverse reactions highlight the risks and uncertainties it faces in the weight loss drug market.
- FDA Breakthrough Therapy Designation: Despite mixed phase 2 data in MASH, pemvidutide received Breakthrough Therapy designation from the FDA, indicating its potential in high unmet need areas; if it successfully passes phase 3 trials, it could significantly enhance Altimmune's market value.
- Novo Nordisk's Market Position: Facing competition from Eli Lilly, Novo Nordisk has lowered its sales guidance, yet with the approval of Wegovy and the launch of a new oral GLP-1 drug, it is poised for recovery in the coming years, demonstrating a stronger market outlook.
- Investor Outlook: 2026 is seen as a transition year for Novo Nordisk; although sales may decline this year, the anticipated impact of new approvals and label expansions is expected to gradually boost revenue, showcasing its long-term investment value in the weight loss drug market.
See More
Altimmune to Report Q4 2025 Financial Results on March 5
- Earnings Report Schedule: Altimmune is set to release its Q4 2025 financial results on March 5, 2026, providing crucial insights into the company's financial health and future growth trajectory, which is vital for investor confidence.
- Conference Call Details: Management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and answer investor questions, with the call being webcast live on the company's Investor Relations website to ensure transparency and timely information dissemination.
- Replay Availability: A replay of the conference call will be accessible on the Investor Relations website shortly after the call, available for up to three months, allowing investors who cannot attend live to catch up on key insights and discussions.
- Company Background: Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, with its lead candidate pemvidutide targeting metabolic dysfunction-associated steatohepatitis and showing promising market potential, which could significantly impact its growth prospects.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
- Analyst Support: On February 13, Titan Partners initiated coverage of Altimmune (NASDAQ:ALT) with a Buy rating and a $7 target, highlighting promising Phase II results for pemvidutide, suggesting potential for stock price appreciation if Phase III data is strong.
- Successful Financing: On January 29, Altimmune closed a direct offering of 17.05 million shares, generating $75 million in gross proceeds, with plans to use net proceeds to fund the upcoming Phase 3 trial of pemvidutide, thereby enhancing financial flexibility.
- FDA Designation: Pemvidutide has received Breakthrough Therapy Designation from the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH), indicating its potential in addressing obesity and liver diseases, which boosts investor confidence.
- Long-Term Outlook: Despite Evercore ISI lowering Altimmune's price target from $25 to $22, the firm reiterated its Outperform rating, reflecting optimism about pemvidutide's long-term prospects and the rationale behind its therapeutic approach.
See More
